784 related articles for article (PubMed ID: 28756138)
21. Mutant p53 reactivation by small molecules makes its way to the clinic.
Bykov VJ; Wiman KG
FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
[TBL] [Abstract][Full Text] [Related]
22. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Mohell N; Alfredsson J; Fransson Å; Uustalu M; Byström S; Gullbo J; Hallberg A; Bykov VJ; Björklund U; Wiman KG
Cell Death Dis; 2015 Jun; 6(6):e1794. PubMed ID: 26086967
[TBL] [Abstract][Full Text] [Related]
23. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
[TBL] [Abstract][Full Text] [Related]
24. Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells.
Tang M; Crown J; Duffy MJ
Invest New Drugs; 2023 Aug; 41(4):541-550. PubMed ID: 37233863
[TBL] [Abstract][Full Text] [Related]
25. Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches.
Roszkowska KA; Piecuch A; Sady M; Gajewski Z; Flis S
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362074
[TBL] [Abstract][Full Text] [Related]
26. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.
Liu DS; Read M; Cullinane C; Azar WJ; Fennell CM; Montgomery KG; Haupt S; Haupt Y; Wiman KG; Duong CP; Clemons NJ; Phillips WA
Gut; 2015 Oct; 64(10):1506-16. PubMed ID: 26187504
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants.
Nagourney AJ; Gipoor JB; Evans SS; D'Amora P; Duesberg MS; Bernard PJ; Francisco F; Nagourney RA
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36981018
[No Abstract] [Full Text] [Related]
28. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
[TBL] [Abstract][Full Text] [Related]
29. Targeting mutant p53 for cancer therapy: direct and indirect strategies.
Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M
J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722
[TBL] [Abstract][Full Text] [Related]
30. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.
Zhang Q; Bykov VJN; Wiman KG; Zawacka-Pankau J
Cell Death Dis; 2018 May; 9(5):439. PubMed ID: 29670092
[TBL] [Abstract][Full Text] [Related]
31. Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.
Hang W; Yin ZX; Liu G; Zeng Q; Shen XF; Sun QH; Li DD; Jian YP; Zhang YH; Wang YS; Quan CS; Zhao RX; Li YL; Xu ZX
Oncogene; 2018 Jun; 37(25):3384-3398. PubMed ID: 29348462
[TBL] [Abstract][Full Text] [Related]
32. SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than
Fujihara KM; Corrales Benitez M; Cabalag CS; Zhang BZ; Ko HS; Liu DS; Simpson KJ; Haupt Y; Lipton L; Haupt S; Phillips WA; Clemons NJ
Mol Cancer Ther; 2021 Oct; 20(10):1858-1867. PubMed ID: 34315763
[TBL] [Abstract][Full Text] [Related]
33. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.
Rökaeus N; Shen J; Eckhardt I; Bykov VJ; Wiman KG; Wilhelm MT
Oncogene; 2010 Dec; 29(49):6442-51. PubMed ID: 20818419
[TBL] [Abstract][Full Text] [Related]
34. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
Yoshikawa N; Kajiyama H; Nakamura K; Utsumi F; Niimi K; Mitsui H; Sekiya R; Suzuki S; Shibata K; Callen D; Kikkawa F
Oncol Rep; 2016 May; 35(5):2543-52. PubMed ID: 26986846
[TBL] [Abstract][Full Text] [Related]
35. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
[TBL] [Abstract][Full Text] [Related]
36. Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.
Bykov VJ; Zhang Q; Zhang M; Ceder S; Abrahmsen L; Wiman KG
Front Oncol; 2016; 6():21. PubMed ID: 26870698
[TBL] [Abstract][Full Text] [Related]
37. Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?
Lim DV; Woo WH; Lim JX; Loh XY; Soh HT; Lim SYA; Lee ZY; Yow HY; Hamzah SB; Sellappans R; Foo JB
Curr Mol Pharmacol; 2024; 17(1):e140923221042. PubMed ID: 37711005
[TBL] [Abstract][Full Text] [Related]
38. Targeting mutant p53 in human tumors.
Lehmann BD; Pietenpol JA
J Clin Oncol; 2012 Oct; 30(29):3648-50. PubMed ID: 22965952
[No Abstract] [Full Text] [Related]
39. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ).
Degtjarik O; Golovenko D; Diskin-Posner Y; Abrahmsén L; Rozenberg H; Shakked Z
Nat Commun; 2021 Dec; 12(1):7057. PubMed ID: 34862374
[TBL] [Abstract][Full Text] [Related]
40. Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
Duffy MJ; Tang M; Rajaram S; O'Grady S; Crown J
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]